Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Lancet Lond Engl, vol.376, pp.1164-74, 2010. ,
Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.26, issue.5, pp.78-84, 2015. ,
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia, Blood, vol.126, pp.1921-1925, 2015. ,
Fludarabine, cyclophosphamide, and rituximab treatment achieves longterm disease-free survival in IGHV-mutated chronic lymphocytic leukemia, Blood, vol.127, pp.303-312, 2016. ,
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial, Blood, vol.127, pp.208-223, 2016. ,
FCR achieves long-term durable remissions in patients with IGHV-mutated CLL, Blood, vol.130, pp.2278-82, 2017. ,
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.980-988, 2012. ,
Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group, J Clin Oncol Off J Am Soc Clin Oncol, 2016. ,
Minimal residual disease is an independent predictor for 10-year survival in CLL, Blood, vol.128, pp.2770-2773, 2016. ,
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, N Engl J Med, vol.370, pp.1101-1111, 2014. ,
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.3209-3225, 2012. ,
Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia, Haematologica, vol.98, pp.65-70, 2013. ,
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines, Blood, vol.111, pp.5446-56, 2008. ,
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, vol.131, pp.2745-60, 2018. ,
Minimal residual disease (MRD) re-growth kinetics are an independent predictor for progression free survival (PFS) in chronic lymphocytic leukemia (CLL) and are related to biologically defined CLLsubgroups-results from the CLL8 trial of the German CLL study group (GCLLSG), Blood, vol.118, pp.1777-1784, 2011. ,
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease, Blood, vol.117, pp.5463-72, 2011. ,
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia, Blood, vol.112, pp.975-80, 2008. ,
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia, Leukemia, vol.21, pp.956-64, 2007. ,
Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL, Leukemia, vol.27, pp.142-151, 2013. ,
A complementary role of multiparameter flow cytometry and highthroughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study, Leukemia, vol.30, pp.929-965, 2016. ,
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial, Lancet Oncol, vol.17, pp.928-970, 2016. ,
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients, J Antimicrob Chemother, vol.71, pp.2397-404, 2016. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01405235
The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS cohort study group, N Engl J Med, vol.322, pp.161-166, 1990. ,
Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 study of the German CLL study group), Blood, vol.128, pp.229-238, 2016. ,
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, Lancet Haematol, vol.4, pp.534-577, 2017. ,
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL), Blood, vol.121, pp.4137-4178, 2013. ,
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer, Blood, vol.120, pp.1412-1433, 2012. ,
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?, Blood, vol.124, pp.2184-2193, 2014. ,
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia, Haematologica, vol.102, pp.494-500, 2017. ,
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes, Blood, vol.122, pp.2539-2588, 2013. ,
Disruption of in vivo chronic lymphocytic leukemia tumormicroenvironment interactions by Ibrutinib--findings from an investigatorinitiated phase II study, Clin Cancer Res Off J Am Assoc Cancer Res, vol.22, pp.1572-82, 2016. ,
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number, Oncotarget, vol.8, pp.34661-34670, 2017. ,
Ibrutinib treatment improves T cell number and function in CLL patients, J Clin Invest, vol.127, pp.3052-64, 2017. ,
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in Bchronic lymphocytic leukemia: implication for maintenance immunotherapy, Leukemia, vol.24, pp.1310-1316, 2010. ,
Regulatory T-cells drive immune dysfunction in CLL, Leuk Lymphoma, vol.2017, pp.1-4 ,
Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia, Int J Cancer, vol.135, pp.2370-2379, 2014. ,
Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia, Leuk Res, vol.60, pp.74-81, 2017. ,
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival, Hematol Oncol, vol.36, pp.128-163, 2018. ,
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912), Blood, vol.132, issue.1, 2018. ,
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL, Blood, vol.123, pp.3727-3759, 2014. ,
Extracellular vesicles released by CD40/IL-4-stimulated CLL cells confer altered functional properties to CD4+ T cells, Blood, vol.128, pp.542-52, 2016. ,
IL-4 enhances expression and function of surface IgM in CLL cells, Blood, vol.127, pp.3015-3040, 2016. ,
Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia, J Cancer Res Clin Oncol, vol.144, pp.449-57, 2018. ,
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations